AstraZeneca Shares Plunge as Heart Disease Drug Trial Fails

AstraZeneca's stock value fell by more than £20 billion following disappointing results from a clinical trial for its heart disease drug, Wainua. The pharmaceutical company's shares dropped 10.5% in early trading on July 9, 2026, ultimately closing down 6.2% at 13,354 pence, an eight-month low. This decline erased approximately £23 billion from the company's market capitalization.

The trial failure represents a significant setback for AstraZeneca and its partner Ionis, as the drug was considered a potential blockbuster capable of generating substantial revenue. The experimental treatment, Wainua, was being tested for its ability to reduce deaths related to transthyretin-mediated amyloid cardiomyopathy, a progressive and often fatal condition affecting an estimated 300,000 to 500,000 people globally. Wainua works by suppressing the production of abnormal proteins in the liver that can impact tissues throughout the body.

This development comes after U.S. regulators previously rejected a breast cancer drug from AstraZeneca in May. The company had been relying on Wainua as part of a strategy to launch up to 20 new drugs by 2030, aiming to achieve £60 billion in annual revenues by that year.

Market analysts expressed concern over the trial's outcome. Chris Beauchamp, chief market analyst at IG, stated that the news is a "major blow" and that the "ambitious targets for 2030 now look under serious threat" given that the expected revenue benefits from this drug will not materialize. Neil Wilson, investor strategist at Saxo, echoed this sentiment, noting it as a disappointment, particularly in light of recent regulatory delays for a cancer drug.

Sharon Barr, AstraZeneca's executive vice-president of biopharmaceuticals research and development, acknowledged that the trial did not meet its primary objective. However, she indicated that the results offer valuable scientific insight into treatment approaches for patients with the condition. Analysts suggest that beyond the potential loss of revenue, the failure may also impact AstraZeneca's credibility, given the company's reputation for robust clinical trials that rarely yield negative results.

Prior to this setback, AstraZeneca's stock had reached a record high of 15,730 pence in February, valuing the company at £244 billion. As of the close of trading on July 9, 2026, its market value stood at £206 billion, making it the second-largest company on the London stock market, trailing HSBC.